Cosmo N.V.: directors' dealings · Switzerland · SIX SER

About Cosmo N.V.

Cosmo N.V. is a life sciences company listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland, and it is followed by investors for its exposure to specialty healthcare innovation rather than broad-based pharma. Founded in 1997, the group has evolved into a focused, multi-platform company positioned at the intersection of medical technology, dermatology, gastroenterology, and contract development and manufacturing (CDMO). This structure gives Cosmo a hybrid profile: it develops proprietary assets, monetizes technology through partnerships, and also captures recurring industrial revenue through manufacturing and development contracts. Cosmo’s business model is built around addressing high-value, underserved medical needs. In gastroenterology, the company is best known for its AI-enabled endoscopy solutions, including the GI Genius ecosystem, which supports clinicians with real-time detection and workflow-enhancing tools during procedures. In dermatology, Cosmo is advancing targeted treatments for indications where demand remains high and differentiated therapies can command attractive pricing. Its CDMO activities add a third leg to the business, providing formulation, development, and manufacturing services to pharmaceutical and medtech partners. Together, these businesses create a diversified but still highly specialized healthcare platform. From a competitive standpoint, Cosmo operates in niches where success depends on clinical innovation, regulatory execution, intellectual property, and commercial partnerships. The company collaborates with major global partners such as Medtronic and Sun Pharma, which helps validate its technology and extend its market reach. This partnership-led approach also reduces the burden of building a large proprietary sales organization in every market. At the same time, investors should view Cosmo as a company with meaningful execution risk: product development timelines, regulatory approvals, reimbursement dynamics, and partnership momentum are all key to the equity story. Geographically, Cosmo is international by design. It was founded in 1997 and is headquartered in Dublin, Ireland, with offices in San Diego, USA, and in Lainate, Rome, and Catania, Italy. That footprint reflects a transatlantic operating model, combining access to US commercialization channels, European industrial capabilities, and global life sciences talent. For Swiss investors, it is particularly relevant that the company is quoted in Switzerland on the SIX Swiss Exchange and that management transactions are reported through the SIX framework. Recent company news points to strengthening operational momentum. Cosmo published its Annual Report 2024 in March 2025, then reported strong first-half 2025 performance and raised full-year EBITDA guidance. It also highlighted accelerating recurring revenue growth across AI and dermatology, while announcing important clinical progress for clascoterone in male androgenetic alopecia. In parallel, the company has continued to expand its AI ecosystem in endoscopy through certifications and product rollouts. Overall, Cosmo presents itself as a growth-oriented specialty healthcare group with a strong innovation narrative, an international footprint, and a shareholder story tied to platform expansion rather than mature pharma cash flows.